Home > Back to Publisher > Report Information

Respiratory Therapeutics and Devices Markets

TriMark Publications
May 1, 2011
158 Pages - SKU: TRI6276740

Abstract Table of Contents Related Reports

Respiratory Therapeutics and Devices Markets

In the respiratory therapeutics and devices market, continuing new advancements in the ability to detect and manage respiratory diseases are being made. The respiratory disease space is one of the most profitable sectors of therapeutics, and it is expected to be growing vigorously into the future. This TriMark Publications report analyzes various respiratory therapeutics and devices markets, with special attention paid to therapeutic remedies for chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Also addressed in this study are therapeutics for upper respiratory infections such as: allergic rhinitis, influenza, respiratory syncytial virus, sinusitis, and pharyngitis/tonsillitis.

From respiratory devices side, key segments covered include: continuous positive airway pressure (CPAP) devices, ventilators, nebulizers, oxygen concentrators, humidifiers and reusable resuscitators. This review covers the leading market players, the competitive landscape, and the emerging pipeline products in the respiratory therapeutics and devices markets. Specifically, areas examined in this study include: available and developing technologies in the field, the U.S. and global market size for respiratory therapeutic products, and the profiles of companies that are focusing on the respiratory therapeutics and devices market. This review analyzes the size and growth of the therapeutic respiratory disease category, including the factors that influence the various market segments within it. Detailed charts with sales forecasts and market share data for the U.S. and global respiratory therapeutics and devices markets are included.

1. Overview: 1.1 Statement of Report; 1.2 About This Report; 1.3 Scope of the Report; 1.4 Objectives; 1.5 Methodology; 1.6 Executive Summary
2. Respiratory Epidemiological Analysis: 2.1 COPD; 2.2 Asthma; 2.3 Upper Respiratory Infections; 2.4 Cystic Fibrosis
3. Major Drug Classes in Treating Respiratory Diseases: 3.1 Leukotriene Inhibitors; 3.2 Corticosteroids; 3.3 Beta-2 (Adrenmoreceptor) Agonists; 3.4 Antihistamines; 3.5 Monoclonal Antibodies
4. Global Market Analysis—Leading Therapeutics and Players: 4.1 COPD Market Analysis; 4.2 Asthma Market Analysis; 4.3 Cystic Fibrosis Market Analysis; 4.4 Respiratory Syncytial Virus Market Analysis; 4.5 Allergic Rhinitis Market Analysis
5. The Respiratory Pipeline—Analysis of Future Therapeutics: 5.1 The COPD Market; 5.2 The Asthma Market; 5.3 The Cystic Fibrosis Market; 5.4 Influenza Market
6. The Respiratory Care Devices Market: 6.1 Aerosol Generation and Efficient Delivery; 6.2 Medication Delivery Systems; 6.3 Nebulizers; 6.4 Dry Powder Inhalers; 6.5 Pressurized Metered-Dose Inhalers; 6.6 Ventilators Market; 6.7 Pulmonary Function Testing Equipment—Spirometry; 6.8 Sleep Apnea Therapeutic Devices Market—CPAP/Bi-level Devices; 6.8.1 CPAP Equipment Gain Popularity in the Pre-Hospital Setting; 6.9 Humidifiers; 6.10 Oxygen Equipment; 6.11 Reusable Resuscitators
7. Respiratory Care Industry Market Analysis: 7.1 Medication Delivery System Market Analysis; 7.2 Medical Ventilator Market analysis; 7.3 Pulmonary Function Test Market Analysis; 7.4 Continuous Positive Airway Pressure Therapy Market Analysis; 7.5 Humidifier Market Analysis; 7.6 Long Term Oxygen Treatment Market Analysis; 7.7 Reimbursement Cuts Negatively Affect the Respiratory Market; 7.8 Growing Incidence Rates for Respiratory Disorders to Propel Demand for Respiratory Devices; 7.9 Availability of Reimbursement in the U.S. to Drive Sales of Respiratory Devices; 7.10 Growth in Home Healthcare to Result in Increased Demand for Respiratory Devices in the Future; 7.11 Development of Technologically Advanced and User Friendly Systems to Increase Adoption of Respiratory Devices
8. SWOT Analysis of the Respiratory Market: 8.1 Biopharmaceutical Industry—Key Aspects of 2010; 8.2 Main Drivers for Respiratory Therapeutics; 8.3 Main Restraints for Respiratory Therapeutic and Device Market; 8.4 Challenges of Respiratory Therapeutics and Devices Going Forward; 8.5 An Emerging Market: Focus on Chinese Health Biotechnology Market; 8.6 Summary of Market Strengths, Weaknesses, Opportunities and Threats
9. Major Players in the Respiratory Market: 9.1 Aerogen; 9.2 Altana AG; 9.3 Aradigm; 9.4 AstraZeneca; 9.5 Boehringer Ingelheim; 9.6 CareFusion; 9.7 Covidien; 9.8 DeVilbiss Healthcare; 9.9 Drager; 9.10 Fisher & Paykel Healthcare; 9.11 GlaxoSmithKline; 9.12 Merck & Co.; 9.13 Nektar Therapeutics; 9.14 Novartis; 9.15 Pfizer; 9.16 ResMed; 9.17 Respironics; 9.18 Roche; 9.19 Schering-Plough; 9.20 Sepracor
INDEX OF FIGURES: Figure 1.1: Smoking Culture Segmentation of the U.S. Population; Figure 1.2: Smoking Trends of U.S. Male and Female Population; Figure 1.3: Current Smoking Trends in U.S. by Ethnicity; Figure 2.1: COPD is the Fourth Main Killer in the U.S., 2006; Figure 2.2: COPD Death Rates in the U.S., 1999-2006; Figure 2.3: Age-standardized Death Rate for COPD in the U.S., 1999-2006; Figure 2.4: Chronic Bronchitis in the Lungs; Figure 2.5: Emphysema of the Lungs; Figure 2.6: Pulmonary and Systemic Inflammation in Acute COPD Exacerbations; Figure 2.7: Management of Patients with Moderate to Severe Exacerbations of COPD; Figure 2.8: Economic Impact of COPD; Figure 2.9: International Asthma Prevalence Ranking; Figure 2.10: Percentage Asthma Prevalence in the U.S.; Figure 2.11: Self-reported Lifetime Asthma Prevalence Rate by State in the U.S.; Figure 2.12: Self-reported Current Asthma Prevalence Rate by State in the U.S.; Figure 2.13: Ratio of Adult Self-reported Current to Lifetime Asthma by State in the U.S.; Figure 2.14: Asthma Prevalence by Age, Sex and Race in the U.S.; Figure 2.15: Prevalence of Current Asthma among Persons of All Ages in the U.S., 2001-2009; Figure 2.16: Prevalence of Current Asthma among Persons of All Ages by Age Group and Sex in the U.S., 2009; Figure 2.17: The Epithelial-Mesenchymal Trophic Unit in Asthma; Figure 2.18: Stepwise Asthma Treatment; Figure 2.19: Economic Burden of Asthma on U.S. Economy, 1992-2010; Figure 2.20: Percentage of Diagnostic Tests Used by Healthcare Providers to Diagnose Allergic Rhinitis in Children; Figure 2.21: Percentage of Allergic Rhinitis Incidence by Season; Figure 2.22: Top Triggers of Allergic Rhinitis in Population; Figure 2.23: Percentage of Respiratory Specimens that Tested Positive for Influenza, October 2010; Figure 2.24: Geographic Areas with Confirmed Human Cases of H5N1 Avian Influenza since January 2010; Figure 2.25: Number of Reported and Confirmed Cases of Influenza H1N1 Strain Worldwide; Figure 2.26: Detailed Structure of the Throat and Pharynx; Figure 2.27: Prevalence of Cystic Fibrosis in the U.S. and Europe; Figure 2.28: European Prevalence per 10,000 Population of Cystic Fibrosis; Figure 2.29: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Structure; Figure 2.30: Pathogenesis of Cystic Fibrosis; Figure 3.1: Leukotriene Inhibitor Biochemical Pathway; Figure 3.2: Corticosteroid Biosynthetic Endogenous Pathway; Figure 4.1: Global Pharmaceutical Sales, 2008-2010; Figure 4.2: Global Segmentation of Pharmaceutical Sales, 2009; Figure 4.3: Percentage of World Market by Geographic Region; Figure 4.4: COPD Market Percentage Share by Country Market; Figure 4.5: Global Advair Sales by Market, 2010; Figure 4.6: Prescription Respiratory World Market Share Differentiated by Disease State; Figure 4.7: Worldwide Prevalence of COPD; Figure 4.8: Top Blockbuster COPD Therapeutics Global Sales, 2009; Figure 4.9: Percentage Market Share of Leading Asthma Pharmaceuticals; Figure 4.10: Top Selling Global Asthma Therapeutics; Figure 4.11: Global Sales of the Major Players in the Asthma Market; Figure 4.12: Cystic Fibrosis Market Forecast, 2010 and 2015; Figure 4.13: Potential Patient Pool requiring Respiratory Syncytial Virus Treatment; Figure 4.14: Market Dynamics of Main Respiratory Syncytial Virus Therapeutic Agents, 2007-2015; Figure 4.15: Global Market Segmentation of Allergic Rhinitis; Figure 5.1: Market Share of Specific Therapeutic Classes for COPD, 2002-2007; Figure 5.2: Percentage Share of Novel COPD Therapeutics in Clinical Development, 2009; Figure 5.3: Mechanisms by which Sensitized Mast Cells can be Inhibited in Asthma; Figure 5.4: Major Market Forecast for Cystic Fibrosis Therapeutics, 2010 and 2015; Figure 5.5: Prevalence of Cystic Fibrosis Patients in Major Markets; Figure 5.6: Global Influenza Market Segmentation, 2007-2014; Figure 5.7: Vaccine Sales of Major Pharmaceutical Companies, 2009; Figure 5.8: Vaccine Providers and Number of Doses Provided for the U.S. Market: The 2000/2001 to 2008/2009 Influenza Season; Figure 5.9: U.S. Vaccine Supply versus Demand for Influenza Seasons 2003/2004 to; 2008/2009; Figure 5.10: U.S. Population Recommended Receiving the Influenza Vaccine for Seasons 2003/2004 to 2008/2009; Figure 5.11: Percentage of Influenza Vaccine Doses Produced that were Distributed for Seasons 2003/2004 to 2008/2009; Figure 5.12: Seasonal Influenza Vaccine Market Size and Forecast, 2005/2006 to 2012/2013; Figure 6.1: Number of Models of Reusable Resuscitators According to Price Range; Figure 6.2: Distribution of Resuscitator Manufacturers Globally; Figure 7.1: Market Segmentation for Resmed Sales, 2008-2010; Figure 7.2: Percentage Sales by Geographic Region, Fisher & Paykel, 2010; Figure 8.1: Number of Approved Biopharmaceuticals in Five Major Markets, 1998-2009; Figure 8.2: Projected Replacement Ratios for Large Pharmaceutical Companies; Figure 8.3: Total Number of Biopharmaceutical Deals, 2007-2010; Table 1.1: Key Facts on Chronic Obstructive Pulmonary Disease (COPD); Table 1.2: Key Facts on Asthma; Table 2.1: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by Current Occupation and Smoking Status, U.S. Females Age 18 and Over, 1997-2004; Table 2.2: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by Current Occupation and Smoking Status, U.S. Males Age 18 and Over, 1997-2004; Table 2.3: COPD Risk Factors Source GOLD; Table 2.4: GOLD Criteria for COPD Staging Based on Post-Bronchodilator FEV1; Table 2.5: Primary indications of COPD Pathogenesis Source GOLD; Table 2.6: Inhaled Corticosteroids Used in the Management of COPD; Table 2.7: Advantages and Disadvantages of Inhaled Delivery Systems for COPD; Table 2.8: Top COPD Inhalers on the Market; Table 2.9: Symptoms of Asthma; Table 2.10: Triggers of Asthma; Table 2.11: Symptoms of an Asthma Attack; Table 2.12: Exacerbating Factors that may lead to an Asthma Attack; Table 2.13: Mechanisms of Allergen Immunotherapy; Table 2.14: Economic Cost of Asthma in the U.S., 2010; Table 2.15: International Costings of Asthma Exacerbations by Disease Severity; Table 2.16: Main Symptoms of Patients with Cystic Fibrosis; Table 2.17: Classifications of Mutations Attributed to Cystic Fibrosis; Table 2.18: Age-specific Presentations of Cystic Fibrosis; Table 2.19: Cystic Fibrosis Disease Management; Table 2.20: Current Respiratory Treatment for Cystic Fibrosis; Table 2.21: Key Novel Cystic Fibrosis Therapeutics; Table 2.22: Drug Development Pipeline Funded by the Cystic Fibrosis Foundation; Table 4.1: Common Beta-2 Agonist Treatments for COPD; Table 4.2: Common Anticholinergic Treatments for COPD; Table 4.3: Common Inhaled Glucocorticosteroid Treatments for COPD; Table 4.4: Combination Short-Acting Beta-2 Agonist and Anticholinergic Treatment for COPD; Table 4.5: Combination Short-Acting Beta-2 Agonist and Inhaled Glucocorticosteroid Treatment for COPD; Table 4.6: Global Market Forecast for the COPD/Asthma Market, 2011-2019; Table 4.7: COPD Market—Market Drivers Ranked in Order of Impact; Table 4.8: COPD Market—Market Restraints Ranked in Order of Impact; Table 4.9: What to Expect from the COPD Market; Table 4.10: Global Market Forecast for the COPD/Asthma Market, 2011-2019; Table 4.11: Asthma Market—Market Drivers Ranked in Order of Impact; Table 4.12: Asthma Market—Market Restraints Ranked in Order of Impact; Table 4.13: What to Expect from the Asthma Market; Table 4.14: Cystic Fibrosis Market—Market Drivers Ranked in Order of Impact; Table 4.15: Cystic Fibrosis Market—Market Restraints Ranked in Order of Impact; Table 4.16: What to Expect from the Cystic Fibrosis Market; Table 4.17: Pipeline Therapeutics against Respiratory Syncytial Virus; Table 5.1: New COPD Mediator Antagonist Therapeutics in Clinical Development; Table 5.2: COPD Pipeline Therapeutics Currently in Development; Table 5.3: Recent Deals between Major Vaccine Pharmaceutical Companies and Domestic Companies in Emerging Markets; Table 6.1: Global Respiratory Devices Market Growth Forecast, 2009-2016; Table 6.2: Factors that Promote Inefficient Aerosol Delivery in Children; Table 6.3: Advantages and Disadvantages of Respiratory Medication Delivery Systems; Table 6.4: Aerosol Therapeutics Available or Under Development; Table 6.5: Inhalation Therapeutics Available for Nebulizer Use; Table 6.6: New Generation Nebulizers; Table 6.7: Dry Powder Inhalers on the Market; Table 6.8: Pressurized Metered Dose Inhalers on the Market; Table 6.9: Mechanisms of Action of Continuous Positive Airway Pressure (CPAP); Table 6.10: Advantages and Disadvantages of Non-invasive Positive Pressure Ventilation; Table 6.11: CPAP Device Considerations for the Pre-Hospital Setting; Table 6.12: Types of Humidifiers Available on the Market; Table 6.13: Challenges to Oxygen Delivery Technology; Table 6.14: Resuscitator Manufactures in China and Taiwan; Table 6.15: Resuscitator Manufactures in Europe; Table 6.16: Resuscitator Manufactures in India; Table 6.17: Resuscitator Manufactures in the U.K.; Table 6.18: Resuscitator Manufactures in the U.S.; Table 6.19: Price Comparison of Reusable Resuscitators on the Market; Table 7.1: Key Factors Driving the Respiratory Care Industry; Table 7.2: Key Drivers of the Global Ventilator Market; Table 7.3: Key Growth Factors in the Sleep Apnea Therapeutic Devices Market; Table 7.4: Key Restraints in the Sleep Apnea Therapeutic Devices Market; Table 7.5: Economic and Geographic Determinants of Global Reimbursement Cuts; Table 7.6: Hospital Costs due to Reimbursement Changes in Healthcare Reform Law; Table 7.7: Growing Incidence Rates for Respiratory Disorders; Table 8.1: Top Ten Selling Biopharmaceuticals, 2009; Table 8.2: Top Ten Biopharmaceutical Drops, 2010; Table 8.3: Key Merger and Acquisition Deals, 2010; Table 8.4: BioPharmaceutical Therapeutics Facing Patent Expiration in the U.S.; Table 8.5: Potential Challenges of Respiratory Therapeutics and Device Market; Table 8.6: Ones to Watch—Chinese Biopharmaceutical Companies on the Up; Table 8.7: Summary of Strengths, Weaknesses, Opportunities and Threats of Respiratory Market

Respiratory Therapeutics and Devices Markets

Share this report

Other tasks

Research Assistance

Related Markets

Respiratory/Pulmonary Reports

Free Alert Me service